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Purpose or Objective: The majority of intraprostatic 
recurrences after radical prostate radiotherapy occur at the 
site of initial tumour, in previous reported series. However, 
there is no published data directly comparing recurrence 
patterns after different modalities of radiotherapy. The aim 
of this study was to investigate differences in spatial pattern 
of intra-prostatic recurrences on multiparametric MRI, after 
external beam radiotherapy or brachytherapy. 
 
Material and Methods: We identified 382 consecutive 
patients referred for multiparametric MRI after previous 
prostate cancer treatment. Patients with post-radiotherapy 
biochemical recurrence and intraprostatic recurrence on MRI 
were included in the study. Scans were independently 
reviewed by two radiologists. The location of recurrence was 
mapped to prostate sectors based on European consensus 
guidelines. The chi-square test was used to analyse 
differences in site of recurrence between modalities of 
radiotherapy. 
 
Results: 66 patients who had radical radiotherapy between 
1997 and 2013 had intraprostatic recurrence on MRI. The 
D’Amico risk stratification at initial diagnosis was 14% low-
risk, 34% intermediate-risk and 52% high-risk. The series 
consisted of 34 patients after external beam radiotherapy 
(EBRT), 20 patients after low-dose rate brachytherapy (LDR) 
and 12 after high-dose rate brachytherapy monotherapy (HDR 
mono). 68% of the EBRT recurrences had received a dose-
fractionation schedule with an EQD2 less than 74 Gy. The 
mean time between the end of radiotherapy and imaging 
recurrence was 77 months (95% CI 68 – 85 months) with no 
significant differences between treatment groups. 80% of 
patients did not have any associated pelvic bony metastasis 
or nodal disease. 88% of patients had a contiguous 
intraprostatic recurrence. The median recurrence size 
detected on MRI was 2.0 cm (range 0.6 – 4.2 cm). 
Recurrences after EBRT were more likely to involve multiple 
sectors of the prostate. 71% of EBRT recurrences involved the 
apex compared to 30% after LDR and 25% after HDR mono (p 
= 0.003). In the LDR group, recurrences involved the base of 
the gland in 60% of cases, compared to 41% after EBRT and 
8% after HDR mono (p = 0.016). 21% of patients underwent 
salvage treatment with cryotherapy, HDR brachytherapy or 
prostatectomy. 
 
Conclusion: Apical recurrences predominated in patients 
following EBRT. This highlights the need for MR-fusion during 
EBRT target definition because the apex is difficult to 
visualise on CT. Basal recurrences were associated with LDR 
brachytherapy, which may reflect a tendency of radioactive 
seed migration away from the base. The use of 
multiparametric MRI facilitates identification of patients for 
focal salvage treatment. 
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Purpose or Objective: The average 5-year survival rate of 
men diagnosed with prostate cancer (PCa) is 93%. The long 
life expectancy exposes them to a greater risk of developing 
second primary cancers. To quantify the risk of radiation 
induced second primary cancer, we analysed data of PCa 
patients based on our Cancer Registry.  
 
Material and Methods: We analysed 19.538 patients treated 
for PCa from 1988 until 2008. They were either treated with 
surgery (RPE only) or received radiation therapy as primary 
(RT only) or as postoperative treatment (RT after RPE). 
Statistical analysis was performed using a stratified Cox 
proportional hazard model and a chi-square test. 
 
Results: Patients who received RT only were 5 years older 
(median) than patients who underwent RPE only or RT after 
RPE. Second primary cancers were observed with 13.1% and 
13.6% in the RPE only and in the RT after RPE group and 
16.4% in the RT only group (p= 0.0001), respectively. Colon 
carcinoma was seen in the RPE only and RT only group in 
roughly 10 percent, whereas in the RT after RPE group in 
14.6% (p= 0.2140). Bronchial cancer surpassed 10% in the RT 
only group (12.5%) vs. 9.7% and 7.8% in the RPE only and the 
RT after RPE group (p= 0.0552). Bladder cancer was observed 
with roughly 10% in the RPE only (10.2%) and RT after RPE 
(10.4%) group versus 15.5% in the RT only group (p= 0.0007). 
Rectal cancer after treatment of PCa was diagnosed in 5.7%, 
7% and 3.1% in the RPE only, RT only and RT after RPE group 
(p= 0.1037). Within the first 10 – 15 years the cumulative 
hazard curves for second primary cancers gave no hint to an 
increased tumor risk due to prior treatment. After 15 years 
there are hardly any cases left and the occurring events can 
no longer be reasonably interpreted. Cox proportional hazard 
ratio revealed that patients with a higher age have a 
significantly higher risk of developing second primary cancer 
(Hazard Ratio 1.279 in 60 - <65 year old patients vs. 2.169 in 
≥75 year old patients, p <0.0001).  
 
Conclusion: Based on this population with PCa from the PSA 
era the incidences of second primary cancers did not differ 
significantly between the three arms apart from bladder and 
lung cancer that came close to being significantly different. 
However, these differences cannot reliably be ascribed to 
radiation, but to other factors such as older age, lifestyle 
habits like smoking and the well known fact that cancer 
survivors generally have an increased risk of new tumor 
formation.  
 
Proffered Papers: Clinical 8: Adult and paediatric CNS 
malignancies  
 
 
OC-0345  
Patterns of failure after radiotherapy in pediatric 
ependymoma: correlation with dose parameters 
F. Tensaouti
1UMR 825 Inserm / Université Toulouse Iii - Paul Sabatier, 
Research, Toulouse, France 
1, A. Ducassou2, S. Bolle3, X. Muracciole4, B. 
Coche-dequeant5, L. Claude6, S. Supiot7, C. Alapetite8, V. 
Bernier9, A. Huchet10, C. Kerr11, E. Le Prise12, G. Truc13, E. 
Regnier14, S. Chapet15, A. Lisbona7, G. Hangard2, A. Laprie2 
2Institut Claudius Regaud Toulouse-  Iuct Oncopole, 
Radiotherapy, Toulouse, France 
3Institut Gustave Roussy- Villejuif, Radiotherapy, Paris, 
France 
4CHU La Timone, Radiotherapy, Marseille, France 
5Centre Oscar Lambret, Radiotherapy, Lille, France 
6Centre Léon Bérard, Radiotherapy, Lyon, France 
7Institut De Cancérologie De L’ouest, Radiotherapy, Nantes, 
France 
8Institut Curie, Radiotherapy, Paris, France 
9Institut De Cancérologie De Lorraine- Alexis Vautrin, 
Radiotherapy, Nancy, France 
10CHU Bordeaux, Radiotherapy, Bordeaux, France 
11Institut Du Cancer De Montpellier, Radiotherapy, 
Montpellier, France 
12Centre Eugène Marquis, Radiotherapy, Rennes, France 
13Centre Georges François Leclerc, Radiotherapy, Dijon, 
France 
14Institut Jean Godinot, Radiotherapy, Reims, France 
15CHU Tours, Radiotherapy, Tours, France 
 
ESTRO 35 2016                                                                                                                                                    S159 
______________________________________________________________________________________________________ 
Purpose or Objective: The aim of this study was to 
investigate the patterns of failure after radiotherapy for 
pediatric intracranial ependymoma and their correlation to 
dose parameters. 
 
Material and Methods: Between 2000 and 2013, 206 patients 
with intracranial ependymoma were treated in the 13 french 
reference pediatric radiotherapy centers . The magnetic 
resonance imaging obtained at recurrence were registered 
with the original planning CT for topographic analysis of the 
patterns failure. Clinical target volume (CTV) and planning 
target volume (PTV) margins were extracted ; several 
dosimetric quality indices were derived from Dose Volume 
Histogram (DVH) to compare relapse with no-relapse patient. 
 
Results: With a median follow-up of 44.81 months (95% CI 
[36.80; 56.51]), 85 (41.3%) patients presented with 
recurrence. The topographic analysis of patterns of failure 
showed 50 (58.8%) patients with local recurrence in the 
radiation field (LF), 6 (4.1%) in the edge of field (EFG), 6 
(7.1%) were loco-regional outside the field (LRF), 8 (9.4%) in 
spine (SF), 5 supratentorial (SUF) and 10 (11.8%) local and 
distant (LDF). The median prescription dose was respectively: 
55.8 Gy [50.4; 60] in LF, 54 Gy [48.6; 59.4] in EF, 56.7 Gy 
[50.4; 60] in LRF, 54 Gy [50.4; 59.4] in LDF, 59.4 Gy [48.6-
59.4] in SUF and 56.7Gy [54; 60] in SF. The median PTV 
margins was 0.5 mm [0.3; 1]. The median Coverage index and 
The Target Coverage index of the PTV were both lower in the 
relapse group as they were respectively 0.97 and 94.8% in the 
relapse group compared with 0.98 and 95.99% in the no-
relapse group. The median Homogeneity index was 0.097 in 
the relapse group versus 0.091 in the no-relapse group. The 
median volume of relapse was 1.29 cc [0.11; 27] in the LF 
group, with a median dose of 58.81 Gy [50.86; 61.38]. 
 
Conclusion: In patients with intracranial ependymoma, local 
failure in the tumor bed was the major pattern of failure. 
The preliminary results showed that all dosimetric indices on 
the PTV were worse in the relapse group. Improving the 
coverage of target volume may be an effective way to reduce 
the local failures. Thus a complementary correlation of 
relapse patterns with dose parameters to PTV and organs at 
risks and the irradiation techniques is under statistical 
analysis and final results will be presented at the meeting. 
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Purpose or Objective: Since 2009 we launched a strategy for 
children with centrally reviewed MRI diagnosis of diffuse 
intrinsic pontine glioma (DIPG) implying the intravenous 
administration of vinorelbine with nimotuzumab –an anti-
EGFR monoclonal antibody- weekly, for a total of 12 weeks, 
during radiotherapy delivery of 54 Gy, 1.8 Gy/fraction daily. 
After radiotherapy completion, vinorelbine and nimotuzumab 
were administered any other week until tumor progression or 
for a total of two years. In the attempt to improve survival 
and quality of life of our children, a protocol amendment in 
July 2011 introduced re-irradiation at relapse/progression. 
 
Material and Methods: Local re-irradiation consisted of 19.8 
Gy, fractionated over 11 days. A 3DCRT with 5-6 coplanar 
beams was adopted with a beam geometry possibly not 
overlapping that of the first line irradiation; the most 
demanding planning issue of re-irradiation was to meet optic 
chiasm dose constraints. Three additional children were re-
irradiated to distant sites of relapse, spine (2) or ventricular 
system at doses of 36 Gy or 54 Gy respectively. 
Results: Of the 39 patients treated from 8/2009, 28 had local 
(23) or disseminated (5) progression and 18 were given local 
(15) or distant (3) relapse re-irradiation at a median of 8 
months after first radiotherapy (2.5-19 months). Reasons for 
not re-irradiating the other 10 children were: progression 
before July 2011 (4), parents refusal (4), too poor Lansky 
status (2); median PFS and progression site were not 
different in the two subgroups. Survival after re-irradiation 
lasted between two weeks and 14 months, median 6 months, 
and determined a statistically difference in median OS 
between the two groups of re-irradiated or not children, 
being 16 and 12 months, respectively (P=0.004). In 16 
radiologically evaluated patients, re-irradiation induced: 
reduction of tumor volume in 8, stable volume in 3 while 5 
had progression; 13 had symptom amelioration and 12 steroid 
suspension. Volume reductions were obtained in 7/8 children 
that have shown the same response after first line irradiation 
while one was obtained after stable disease in first line 
treatment. No adverse event was reported and all children 
were re-irradiated as outpatients . 
 
Conclusion: Re-irradiation after relapse/progression 
represented a significant benefit for both OS and quality of 
life of children with DIPG with symptom amelioration in 
13/18. This option is worth to be offered also in case of 
disseminated progression.  
Partially supported by Associazione Italiana per la Ricerca sul 
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Purpose or Objective: For the treatment of adult patients 
newly diagnosed with medulloblastoma, there is no standard 
to guide multimodality therapy. With a multi-institutional 
cohort, we investigated and reported the multidisciplinary 
approach, clinical outcome, and prognostic factors of 
medulloblastoma in adult patients treated with postoperative 
radiotherapy (RT). 
 
